S.M.A.R.T. AND S.M.A.R.T. CONTROL NITINOL STENT SYSTEM
Cordis US Corporation · Decision date Aug 12, 2003
What did the FDA approve?
The FDA database entry records an August 12, 2003 approval for the S.M.A.R.T. Nitinol Stent System and S.M.A.R.T. Control Nitinol Stent System from Cordis US Corporation. The stated purpose is improving luminal diameter in patients with symptomatic atherosclerotic disease of the common and/or external iliac arteries up to 126 mm in length, with a reference vessel diameter of 4 to 9 mm, and angiographic evidence of a patient profunda or superficial femoral artery.
This is an original PMA approval, not a supplement or manufacturing notice. The entry does not describe a changed item or a relationship to a prior PMA. The statement reports the approved indication as written in the database; it does not independently establish safety or clinical effectiveness. No trial data, technical specifications, or clinical benefit assessments appear in the source fields.
FDA approval order statement
APPROVAL FOR THE S.M.A.R.T. NITINOL STENT SYSTEM AND S.M.A.R.T. CONTROL NITINOL STENT SYSTEM. THE DEVICES ARE INDICATED FOR IMPROVING LUMINAL DIAMETER IN PATIENTS WITH SYMPTOMATIC ATHEROSCLEROTIC DISEASE OF THE COMMON AND/OR EXTERNAL ILIAC ARTERIES UP TO 126 MM IN LENGTH, WITH A REFERENCE VESSEL DIAMETER OF 4 TO 9 MM, AND ANGIOGRAPHIC EVIDENCE OF A PATIENT PROFUNDA OR SUPERFICIAL FEMORAL ARTERY.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 12, 2003
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P020036
- Regulatory pathway
- Premarket approval application
- Applicant
- Cordis US Corporation
- Product code
- NIO
- Decision code
- APPR
- Decision date
- Aug 12, 2003
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, ILIAC.
- Applicant
- Cordis US Corporation
- Product code
- NIO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P020036 received
Application receipt date recorded by FDA.
P020036 · FDA decision
APPR
P020036/S061 · Related supplement
S.M.A.R.T. CONTROL Nitinol Stent System
Timeline entries are records held by MedtechLedger for P020036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P020036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
S.M.A.R.T. CONTROL Nitinol Stent SystemP020036/S061 | Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA |
Explore the linked device profile
Other records with product code NIO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cook Ireland, Ltd. | PMA supplement | Nov 6, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Dec 17, 2015 | FDA | |
ZILVER VASCULAR STENTP050017 | Cook Ireland, Ltd. | PMA approval | Jun 26, 2006 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cordis US Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 14201 NW 60th Ave., Miami Lakes, FL, 33014
Sources and methodology
- Original FDA record: P020036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



